Buschmann Catharina, Fischer Christian, Ochsenhirt Viola, Neukirch Carolin, Lackner Karl J, von Landenberg Philipp
Institute of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.
Ann N Y Acad Sci. 2005 Jun;1051:240-54. doi: 10.1196/annals.1361.065.
Antiphospholipid antibodies (APLs) might be involved in the pathogenesis of the antiphospholipid syndrome (APS). This study analyzes the structural characteristics of monoclonal APLs derived from patients with this disease. Patient-derived B cells were immortalized using Epstein-Barr virus transformation and subsequent fusion to the myeloma cell line CB-F7. APL-producing hybridomas were cloned to obtain cell lines producing monoclonal APL. DNA encoding the variable region of heavy and light chains of the antibodies was sequenced and analyzed regarding their usage within the V-gene family and the existence of somatic hypermutation. Binding patterns of APL to various phospholipids and beta-2-glycoprotein-I (beta2-GPI) were determined using ELISA, with special regard to beta2-GPI dependency. As a result, three APL-producing hybridoma cell lines from patients with APS were established: JGG9, HVA2, and HLC9. APLs were of the IgM isotype and showed different binding patterns toward phospholipids and beta2-GPI. One of them, JGG9, showed extensive somatic hypermutations in both the CDR3 region and a framework region of the heavy chain. JGG9 bound to cardiolipin in the presence of the protein cofactor beta2-GPI. In contrast, the antibodies HVA2 and HLC9 (which also showed somatic hypermutations in the CDR3 region) presented polyreactivity to several phospholipids-cardiolipin, phosphatidyl-serine, -ethanolamine, -inositol, -choline, and sphingomyelin-but not to beta2-GPI. In conclusion, JGG9 presents a high degree of mutation in the CDR3 and framework region resulting from the deletions of nucleotides, and affects amino acid composition. Polyreactivity and the absence of cofactor dependency present HLC9- and HVA2-like natural antibodies that have no contact with any antigen. Nonetheless, these natural antibodies show somatic hypermutation of the heavy chain, indicating antigen-driven maturation. Regarding the possible role of APL in infection, HVA2 in particular may represent a pathogen-maturated antibody showing cross-reactivity between phospholipids and infectious agents. Further experiments are needed to reveal the functional activity of these antibodies.
抗磷脂抗体(APLs)可能参与抗磷脂综合征(APS)的发病机制。本研究分析了源自该疾病患者的单克隆APLs的结构特征。使用爱泼斯坦 - 巴尔病毒转化患者来源的B细胞,随后将其与骨髓瘤细胞系CB - F7融合使其永生化。克隆产生APL的杂交瘤以获得产生单克隆APL的细胞系。对编码抗体重链和轻链可变区的DNA进行测序,并分析其在V基因家族中的使用情况以及体细胞超突变的存在情况。使用酶联免疫吸附测定(ELISA)确定APL与各种磷脂和β2 - 糖蛋白 - I(β2 - GPI)的结合模式,特别关注β2 - GPI依赖性。结果,建立了来自APS患者的三个产生APL的杂交瘤细胞系:JGG9、HVA2和HLC9。APLs为IgM同种型,对磷脂和β2 - GPI表现出不同的结合模式。其中之一JGG9在重链的互补决定区3(CDR3)区域和一个框架区域均显示出广泛的体细胞超突变。JGG9在蛋白质辅因子β2 - GPI存在下与心磷脂结合。相比之下,抗体HVA2和HLC9(其在CDR3区域也显示体细胞超突变)对几种磷脂——心磷脂、磷脂酰丝氨酸、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰胆碱和鞘磷脂表现出多反应性,但对β2 - GPI无反应。总之,JGG9在CDR3和框架区域因核苷酸缺失而呈现高度突变,并影响氨基酸组成。多反应性以及缺乏辅因子依赖性使得HLC9和HVA2样天然抗体不与任何抗原接触。尽管如此,这些天然抗体显示重链体细胞超突变,表明是抗原驱动的成熟。关于APL在感染中的可能作用,特别是HVA2可能代表一种病原体成熟的抗体,显示出磷脂与感染因子之间的交叉反应性。需要进一步的实验来揭示这些抗体的功能活性。